Edition:
India

Nicox SA (NCOX.PA)

NCOX.PA on Paris Stock Exchange

7.99EUR
16 Aug 2018
Change (% chg)

-- (--)
Prev Close
€7.99
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
65,026
52-wk High
€11.60
52-wk Low
€7.66

Latest Key Developments (Source: Significant Developments)

Nicox Initiates Phase 2 Study Of NCX 470 In Open-Angle Glaucoma And Ocular
Thursday, 2 Aug 2018 

Aug 2 (Reuters) - NICOX SA ::NICOX INITIATES PHASE 2 STUDY OF NCX 470 IN OPEN-ANGLE GLAUCOMA AND OCULAR.STUDY TO RANDOMIZE 420 PATIENTS IN CLINICAL SITES ACROSS U.S..TOP-LINE RESULTS EXPECTED H2 2019.TARGETS $5 BILLION WORLDWIDE GLAUCOMA MARKET.INITIATION OF A PHASE 2 CLINICAL STUDY EVALUATING NCX 470.  Full Article

Nicox Plans Start Of Phase 2 Clinical Study For NCX 470 In Q3 2018
Tuesday, 17 Jul 2018 

July 17 (Reuters) - NICOX SA ::NICOX Q2 2018 BUSINESS UPDATE AND FINANCIAL HIGHLIGHTS.Q3 2018: PLANNED START OF PHASE 2 CLINICAL STUDY FOR NCX 470 FOR THE REDUCTION OF INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION.FALL 2018: EXPECTED COMMERCIAL LAUNCH OF ZERVIATETM (CETIRIZINE OPHTHALMIC SOLUTION), 0.24% IN THE UNITED STATES BY PARTNER EYEVANCE PHARMACEUTICALS, LLC..Q1 2019: PLANNED U.S. INVESTIGATIONAL NEW DRUG SUBMISSION TO THE U.S. FDA FOR NCX 4251.AS OF JUNE 30, 2018, THE NICOX GROUP HAD CASH AND CASH EQUIVALENTS OF €32.6 MILLION VERSUS €36.3 MILLION AT MARCH 31, 2018.VYZULTA SALES GREW SUBSTANTIALLY IN THE Q2.  Full Article

Sellas Life Sciences Announces Appointment Of Gene Mack As Chief Financial Officer & Treasurer
Friday, 20 Apr 2018 

April 20 (Reuters) - Sellas Life Sciences Group Inc ::SELLAS LIFE SCIENCES ANNOUNCES APPOINTMENT OF GENE MACK AS CHIEF FINANCIAL OFFICER & TREASURER.SELLAS LIFE SCIENCES GROUP INC - INTERIM CHIEF FINANCIAL OFFICER ALEKSEY KRYLOV WILL REMAIN WITH SELLAS UNTIL JULY 15.SELLAS LIFE SCIENCES GROUP INC - MACK MOST RECENTLY SERVED AS A CONSULTING CFO, MOST RECENTLY WITH NICOX, SA.  Full Article

Nicox Updates on Drug Development And Outlines 2018 Activities
Tuesday, 19 Dec 2017 

Dec 19 (Reuters) - NICOX SA ::RESOURCES IN 2018 WILL BE FOCUSED ON ADVANCING NICOX'S PIPELINE CANDIDATES NCX 470 AND NCX 4251 TOWARDS MID-STAGE CLINICAL DEVELOPMENT.ESTIMATES THAT THE U.S. PATENTS COVERING VYZULTA COULD BE EXTENDED FROM 2025 TO 2030..EXPECTS TO BEGIN RECEIVING ROYALTY REVENUE IN 2018, ALONG WITH POTENTIAL SALES AND DEVELOPMENT MILESTONES PAYMENTS‍​.NCX 470 TARGETING IND SUBMISSION FOR PHASE 2 IN 2018.NCX 4251 TARGETING IND SUBMISSION FOR PHASE 2 IN 2018.  Full Article

Bausch + Lomb and Nicox announces FDA approval of Vyzulta
Friday, 3 Nov 2017 

Nov 2 (Reuters) - Valeant Pharmaceuticals International Inc :Bausch + Lomb and Nicox announce FDA approval of Vyzulta™ (latanoprostene Bunod Ophthalmic Solution), 0.024%.Valeant - ‍co's wholly owned subsidiary, Bausch + Lomb and Nicox S.A announced FDA approved NDA for Vyzulta​.  Full Article

Nicox says ‍cash balance was 47.1 million euros as of Sept. 30
Tuesday, 24 Oct 2017 

Oct 24 (Reuters) - NICOX SA ::‍CASH BALANCE OF EUR 47.1 MILLION AS OF SEPTEMBER 30, 2017​.Q3 NO REVENUE ‍​ VERSUS NO REVENUE YEAR AGO.  Full Article

Nicox and pSivida enter collaboration agreement to develop sustained release drug for glaucoma patients​
Tuesday, 10 Oct 2017 

Oct 10 (Reuters) - Nicox SA :Nicox-Co and pSivida enter strategic collaboration agreement to develop sustained release drug to lower intraocular pressure in patients with glaucoma​.Would make additional payments for any incremental development activities for each implant formulation product candidate.Expected payments from Nicox associated with agreement are not considered material to Nicox's financial statements at this time​.Says ‍pSivida will be responsible for initial development activities of ocular insert formulations, for which it will receive undisclosed sums​.  Full Article

Nicox and pSivida enter strategic collaboration agreement
Tuesday, 10 Oct 2017 

Oct 10 (Reuters) - NICOX SA ::REG-NICOX AND PSIVIDA ENTER STRATEGIC COLLABORATION AGREEMENT TO DEVELOP SUSTAINED RELEASE DRUG TO LOWER INTRAOCULAR PRESSURE IN PATIENTS WITH GLAUCOMA.NEW INTELLECTUAL PROPERTY FROM THE COLLABORATION RELATING TO THE DRUG-DEVICE COMBINATION WILL BE JOINTLY OWNED‍​.PSIVIDA TO BE RESPONSIBLE FOR INITIAL DEVELOPMENT ACTIVITIES OF OCULAR INSERT FORMULATIONS, FOR WHICH IT WILL RECEIVE UNDISCLOSED SUMS BY NICOX‍​.  Full Article

Nicox receives complete response letter from FDA for AC-170
Monday, 10 Oct 2016 

Nicox SA : Receives complete response letter from FDA related to GMP on NDA for AC-170 . FDA's stated reason for CRL pertains to good manufacturing practice inspection at a third party facility producing API cetirizine and supplying it to manufacturer of finished product .Safety and efficacy data submitted by Nicox in AC-170 NDA have not resulted in FDA requesting any further clinical or non-clinical testing for approval.  Full Article

BRIEF-Nicox Q1 Net Revenue At 0.075 Million Euros

* AS OF MARCH 31, 2018, THE GROUP HAD CASH AND CASH EQUIVALENTS OF €36.3 MILLION AS COMPARED WITH €41.4 MILLION AT DECEMBER 31, 2017